Evidence map›Paper›PMID 36084109›Full record

ArticlePloS one2022

CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells.

Agathe Reigstad, Christina Frantzen Herdlevær, Emma Rigg, Tuyen Hoang, Ole Vidhammer Bjørnstad, Synnøve Nymark Aasen, Jasmin Preis, Claude Haan, Terje Sundstrøm, Frits Thorsen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Agathe ReigstadDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Christina Frantzen HerdleværDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Emma RiggDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Tuyen HoangDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Ole Vidhammer BjørnstadDepartment of Biomedicine, University of Bergen, Bergen, Norway.
Synnøve Nymark AasenDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0001-7557-3784
Jasmin PreisDepartment of Life Sciences and Medicine, University of Luxembourg, Belvaux, Luxembourg.
Claude HaanDepartment of Life Sciences and Medicine, University of Luxembourg, Belvaux, Luxembourg.
Terje SundstrømDepartment of Neurosurgery, Haukeland University Hospital, Bergen, Norway.
Frits ThorsenDepartment of Biomedicine, University of Bergen, Bergen, Norway.ORCID 0000-0002-7762-3703
University of Bergen · NOUniversity of Luxembourg · LUHaukeland University Hospital · NOWestern Norway University of Applied Sciences · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanomas frequently metastasize to the brain. Despite recent progress in the treatment of melanoma brain metastasis, therapy resistance and relapse of disease remain unsolved challenges. CCT196969 is a SRC family kinase (SFK) and Raf proto-oncogene, serine/threonine kinase (RAF) inhibitor with documented effects in primary melanoma cell lines in vitro and in vivo. Using in vitro cell line assays, we studied the effects of CCT196969 in multiple melanoma brain metastasis cell lines. The drug effectively inhibited proliferation, migration, and survival in all examined cell lines, with viability IC50 doses in the range of 0.18-2.6 μM. Western blot analysis showed decreased expression of p-ERK, p-MEK, p-STAT3 and STAT3 upon CCT196969 treatment. Furthermore, CCT196969 inhibited viability in two B-Raf Proto-Oncogene (BRAF) inhibitor resistant metastatic melanoma cell lines. Further in vivo studies should be performed to determine the treatment potential of CCT196969 in patients with treatment-naïve and resistant melanoma brain metastasis.

Indexed as

Brain NeoplasmsMelanomaCell Line, TumorDrug Resistance, NeoplasmHumansMutationNeoplasm Recurrence, LocalPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrazines1-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydropyrido(3,2-b)pyrazin-8-yloxy)phenyl)ureaPhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyrazines

Identifiers

PMID36084109
PMCPMC9462752
OpenAlexW4295049483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.